Apogee Therapeutics, Inc.

NASDAQ:APGE

Biotechnology

Healthcare
$135.07 +1.18%

+$1.05 today

Market cap
$8.36B
Beta
0.62
P/E (TTM)
-22.7
EPS (TTM)
-$3.94
52W Low $34.34High $95.32

Volume 0.00M

Average 0.97M

APGE Interest Income

Income earned on cash, deposits, and investments held by the company.

Apogee Therapeutics, Inc.NASDAQ: APGE

Interest Income · Q2 FY2026 · quarter ended Jun 2026

Interest income growth accelerates

Q2 FY2026 interest income of $11.81M rose 65.4% year over year, ahead of the -83.3% change in trailing-twelve-month interest income. Sequentially, it rose 35.1% from the prior quarter. Over 3 fiscal years it compounded at +588.5% a year.

Context

  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +65.4% holds above the trailing-twelve-month pace of -83.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$11.81M+35.1% QoQ
Last fiscal yearDec 2025
$30.03M-13.6% YoY
LTMJun 2026
$5.57M-83.3% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+65.4%——
1 year-13.6%——
3-year CAGR+588.5%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
30.03M USD
Year-over-year change
-13.6%
3-year CAGR
+588.5%

Interest Income vs competitors

How APGE compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -83.3% is the lowest of 10, against a peer median of +4.2%.
  • Over three fiscal years its annual growth of +588.5% compares with a peer median of +85.8%.
APGE Competitors
Interest Income for APGE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAPGAscentage Pharma Group InternationalFY2025CN¥79.89M CNY+111.1%+101.8%14.3%
CGONCG Oncology, Inc. Common stockLTM Sep 2026$42.53M USD+48.0%—689.7%
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$36.88M USD+19.3%+45.5%—
ZLABZai Lab LimitedLTM Jun 2026$27.93M USD-21.5%+31.4%6.2%
IRONDisc Medicine, Inc.LTM Sep 2026$27.29M USD+4.2%+239.6%—
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$24.17M USD-30.0%+31.2%3.6%
LEGNLegend Biotech CorporationLTM Sep 2026$23.55M USD-48.6%+69.9%1.7%
CNTACentessa Pharmaceuticals plcLTM Mar 2026$17.78M USD-8.0%+338.2%—
CELCCelcuity Inc.LTM Jun 2026$15.94M USD+45.9%+121.8%—
APGEApogee Therapeutics, Inc.LTM Jun 2026$5.57M USD-83.3%+588.5%—
Peer median (excluding APGE) —+4.2%+85.8%6.2%

Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue0001.42M
Gross Profit000(1.42M)
Gross Margin————
Research & Development27.79M68.42M167.87M214.71M
Selling, General & Admin2.94M24.58M49.01M70.88M
Operating Expenses30.73M93M216.87M284.18M
Depreciation & Amortization09.02M189K1.42M
EBITDA(39.79M)(74.97M)(181.94M)(254.15M)
EBITDA Margin————
Operating Income(30.73M)(93M)(216.87M)(285.6M)
Operating Margin————
Interest Income92K9.02M34.74M30.03M
Interest Expense9.15M000
Other Income / Expenses(9.06M)9.02M34.74M30.03M
Income Before Tax(39.79M)(83.99M)(182.13M)(255.57M)
Pre-Tax Margin————
Income Tax Expense0018K278K
Net Income(39.79M)(83.99M)(182.15M)(255.84M)
Net Margin————
EPS (Basic)(0.79)(1.66)(3.30)(4.22)
EPS (Diluted)(0.79)(1.66)(3.30)(4.22)
Weighted Avg Shares50.67M50.66M55.19M60.69M
Weighted Avg Shares (Diluted)50.67M50.66M55.19M60.69M

Apogee Therapeutics, Inc.

NASDAQ:APGE

Intrinsic Alpha fair value

Locked

Current Price

$135.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.